Results 251 to 260 of about 709,350 (366)

ORL@Cu‐MOF Boost Cuproptosis and Suppress Fatty Acid Metabolism for Cancer Lymph Node Metastasis Synergistic Therapy

open access: yesAdvanced Science, EarlyView.
The fabrication of ORL@Cu‐MOF and the mechanism of synergistic therapy by cuproptosis, reprogram fatty acid metabolism and anti‐PD‐1. Abstract Lymph node metastasis (LNM) is one of the significant characteristics of poor prognosis in oral squamous cell carcinoma (OSCC), strongly associated with high mortality rates.
Zi‐Zhan Li   +11 more
wiley   +1 more source

Abnormal β‐Hydroxybutyrylation Modification of ARG1 Drives Reprogramming of Arginine Metabolism to Promote the Progression of Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Alterations in arginine metabolism and β‐hydroxybutyrylation (Kbhb) modifications play a critical role in tumor progression. This study reveals valuable insights into arginine metabolism reprogramming involving the ARG1‐Kbhb/P300/SLC3A2 signaling axis and uncovers an effective therapy combining BHB with ARG1 inhibitor through conventional enzymatic and
Chuman Lin   +6 more
wiley   +1 more source

An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis. [PDF]

open access: yesCancer Commun (Lond), 2023
Li Y   +10 more
europepmc   +1 more source

Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis [PDF]

open access: bronze, 2018
Brett L. Ecker   +16 more
openalex   +1 more source

Clinical Features, Molecular Biology, and the Metastatic Microenvironment in Lung Cancer Brain Metastases: Implications for Treatment Decisions

open access: yesAdvanced Science, EarlyView.
Brain metastases (BM) from lung cancer are aggressive with poor prognosis. This review covers clinical features, diagnosis, early metastasis, and multi‐omics‐elucidated mechanisms, especially the tumor microenvironment of lung cancer with BM. It also discusses preclinical models, signaling pathways, and emerging therapies.
Yixiang Zhu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy